Clene (CLNN) Total Stockholders Equity : $4.26 Mil (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Clene Total Stockholders Equity?

Clene's Total Stockholders Equity for the quarter that ended in Mar. 2024 was $4.26 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Clene's Book Value per Share for the quarter that ended in Mar. 2024 was $0.03. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Clene's Debt-to-Equity for the quarter that ended in Mar. 2024 was 7.61.

Clene Total Stockholders Equity Historical Data

The historical data trend for Clene's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clene Total Stockholders Equity Chart

Clene Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Total Stockholders Equity

-67.77

0.34

12.60

3.24

13.39

Clene Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Stockholders Equity	Get a 7-Day Free Trial													-1.63	21.53	21.41	13.39	4.26

Clene (NAS:CLNN) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Clene's Book Value per Share for the quarter that ended in Mar. 2024 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(4.264	-	0)	/	128.434
	=	0.03

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Clene's Debt-to-Equity for the quarter that ended in Mar. 2024 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(20.635	+	11.805)	/	4.264
	=	7.61

Clene Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Clene's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Clene (CLNN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clene Inc (NAS:CLNN) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

84C:Germany

Address

6550 South Millrock Drive, Suite G50, Salt Lake City, UT, USA, 84121

Website

https://www.clene.com

Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. Its reportable segments: (1) the development and commercialization of novel clean-surfaced nanotechnology therapeutics (Drugs, and (2) the development and commercialization of dietary supplements (Supplements).

Executives

David J Matlin	director
Matthew Kiernan	director	500 PRINCIPIO PARKWAY WEST, SUITE 400, NORTH EAST MD 21901
Arjun Jj Desai	director	C/O TRISALUS LIFE SCIENCES, INC., 6272 W. 91ST AVENUE, WESTMINSTER CO 80031
Robert Dee Etherington	director, officer: Chief Executive Officer	6550 SOUTH MILLROCK DRIVE, SUITE G50, SALT LAKE CITY UT 84121
John Henry Stevens	director	6550 SOUTH MILLROCK DRIVE, SUITE G50, SALT LAKE CITY UT 84121
Chidozie Ugwumba	director	158 FILMORE STREET, DENVER CO 80206
Alison Mosca	director	26 PATRIOT PLACE, SUITE 301, FOXBORO MA 02035
Jonathon Gay	director	177 HUNTINGTON AVENUE, 21ST FLOOR, BOSTON MA 02115
General Resonance Llc	10 percent owner	6510 SOUTH MILLROCK DRIVE, SUITE 250, HOLLADAY UT 84121
Robert Glanzman	officer: Chief Medical Officer	6550 SOUTH MILLROCK DRIVE, SUITE G50, SALT LAKE CITY UT 84121
Morgan R Brown	officer: Chief Financial Officer	420 CHIPETA WAY, SALT LAKE CITY UT 84108
Vallerie Mclaughlin	director	6550 SOUTH MILLROCK DRIVE, SUITE G50, SALT LAKE CITY UT 84121
Mark Mortenson	officer: Chief Science Officer	500 PRINCIPIO PARKWAY WEST, SUITE 400, NORTH EAST MD 21901
Fiona Costello	director	6550 SOUTH MILLROCK DRIVE, SUITE G50, SALT LAKE CITY UT 84121
Shalom Jacobovitz	director	6550 SOUTH MILLROCK DRIVE, SUITE G50, SALT LAKE CITY UT 84121